Harbor Health Care ETF MEDI
36.25 USD +0.16 (+0.45%)
At closeNov 11, 2026, 4:15 PM EST
36.25 0.00 0.00%
After hours · Nov 11, 4:15 PM ET
36.10 Day range 36.25
27.78 52-week range 36.25
- YTD
- +15.28%
- 1 year
- +17.79%
News
benzinga.com Why Is Ascendis Pharma Stock Trading Lower on Tuesday? Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.
feeds.benzinga.com Why Is Legend Biotech Stock Falling Thursday? Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get the latest technical levels here.
benzinga.com Why Is Legend Biotech Stock Falling Thursday? Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get the latest technical levels here.
zacks.com Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
benzinga.com Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints Rhythm Pharmaceuticals says EMANATE trial misses goals, despite BMI reduction signals and continued pipeline development plans.
seekingalpha.com Harbor Health Care ETF Q4 2025 Portfolio Review Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly…
seekingalpha.com Harbor Health Care ETF Q4 2025 Commentary During the fourth quarter, the Harbor Health Care ETF returned 10.43% (NAV), underperforming the Russell 3000® Growth Health Care Index, which returned 16.71%. The underperformance was primarily…
benzinga.com Why Your Pneumonia Shot Is About To Get A Massive Upgrade Vaxcyte shares rise after starting Phase 3 trials for its VAX-31 pneumonia vaccine, expanding studies in adults and infants while planning major U.S. manufacturing investments.
seekingalpha.com Harbor Health Care ETF Q3 2025 Commentary During the third quarter, the Harbor Health Care ETF returned 7.30% (NAV), outperforming the Russell 3000® Growth Health Care Index, which returned 3.80%. We purchased IDEXX Laboratories, a MedTech…
benzinga.com Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.
seekingalpha.com MEDI Group Readies $15 Million U.S. IPO Plan MEDI Group has filed for a $15 million US IPO, but its revenue is declining from a small base, with negative free cash flow and increased cash used in operations. The IPO valuation appears excessive,…
seekingalpha.com Harbor Health Care ETF Q1 2025 Commentary The Health Care sector rebounded in the first quarter of 2025, navigating a volatile but opportunistic landscape. During the first quarter, the Harbor Health Care ETF returned 2.18% (NAV),…
benzinga.com COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch Over half of US states have high levels of Covid-19 in wastewater as President Biden isolates with virus. New vaccines expected by Sept.
zacks.com ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
zacks.com UnitedHealth Beats on Q4 Earnings, Shares Slip: ETFs in Focus The largest U.S. health insurer UnitedHealth Group (UNH) reported better-than-expected fourth-quarter 2023 results but medical costs rose more than expected for the first time in two years.
zacks.com Eli Lilly Beats on Q3 Earnings: ETFs to Buy Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.
zacks.com UnitedHealth Beats on Q3 Earnings, Raises View: ETFs to Gain UnitedHealth (UNH) reported better-than-expected third-quarter 2023 results. Earnings and revenues breezed past the Zacks Consensus Estimate.
zacks.com Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs…
zacks.com UnitedHealth Beats Q2 Earnings, Updates View: ETFs to Gain UnitedHealth (UNH) reported better-than-expected second-quarter 2023 results, breezing past the Zacks Consensus Estimate for earnings and revenues. The company lifted the lower end of its full-year…
zacks.com ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline,…
etftrends.com Harbor CIO Kristof Gleich: Thematics Help Advisors Connect With Clients Thematic investments are seeing a resurgence in investor interest after developing a – perhaps undeserved and unwarranted – negative reputation in recent years. The economic regime has shifted, and…
etftrends.com 3 Ways to Play iShares' 2023 Hot Takes With ETFs These are the questions on every investor's mind: Have markets really priced in the severity of the Fed's campaign against inflation? How bad would a 2023 recession be — if there is one at all?
etftrends.com Harbor Launches Active Pure Play Healthcare ETF: MEDI Harbor Capital Advisors has launched a new active, fully transparent ETF, providing advisors the opportunity to invest in a pure play healthcare strategy.